Share This Author
- M. Mahoney
- MedicineReactions Weekly
- 1 February 2020
Acne vulgaris is a common human skin disease, characterized by areas of skin with seborrhea , comedones (blackheads and whiteheads), papules , pustules , nodules and possibly scarring. Acne affects…
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.
Update on Treatment Options for Gonococcal Infections
- Jason W. Lancaster, M. Mahoney, Sanatan Mandal, K. Lawrence
- Medicine, BiologyPharmacotherapy
- 1 September 2015
The various agents targeted against N. gonorrhoeae are reviewed, both currently available and under clinical investigation, and recommendations for the management of gonococcal infections are provided.
Clinical Management of an Increasing Threat: Outpatient Urinary Tract Infections Due to Multidrug-Resistant Uropathogens.
- E. Walker, A. Lyman, K. Gupta, M. Mahoney, G. Snyder, Elizabeth B. Hirsch
- MedicineClinical infectious diseases : an official…
- 1 October 2016
Consideration of patient risk factors for resistance and pharmacological principles will help guide optimal empiric treatment of outpatient UTIs.
Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile
Overall, bezlotoxumab demonstrated a 40% relative reduction rate (absolute rate reduction of ~10%) and a number needed to treat of 10 patients with a favorable safety profile, and special populations, including the elderly, immunocompromised, and patients with end-stage renal disease were evaluated in post hoc analyses with a similarly favorable reduction in rCDI.
Bezlotoxumab: Could This be the Answer for Clostridium difficile Recurrence?
- R. Chapin, Tiffany Lee, Christopher M McCoy, C. Alonso, M. Mahoney
- Medicine, BiologyThe Annals of pharmacotherapy
- 6 May 2017
In patients treated with SoC antibiotics, BEZ is effective in decreasing rCDI, and the greatest benefit has been demonstrated in high-risk patients, though the targeted patient population is yet to be defined.
Critical evaluation of ceftolozane–tazobactam for complicated urinary tract and intra-abdominal infections
- S. Giancola, M. Mahoney, T. Bias, Elizabeth B. Hirsch
- Medicine, BiologyTherapeutics and clinical risk management
- 19 May 2016
Current data suggest that ceftolozane–tazobactam is a promising carbapenem-sparing alternative agent for the treatment of cUTIs and cIAIs, including those caused by ESBL-producing Enterobacteriaceae and MDR P. aeruginosa.
Assessment of Fosfomycin for Complicated or Multidrug-Resistant Urinary Tract Infections: Patient Characteristics and Outcomes
- S. Giancola, M. Mahoney, M. Hogan, Brian R. Raux, Christopher M McCoy, Elizabeth B. Hirsch
- Medicine, BiologyChemotherapy
- 28 October 2016
This retrospective study adds to the limited literature exploring alternative therapies for complicated and MDR UTIs with results providing additional evidence that fosfomycin may be an effective oral option.
Eravacycline: The Tetracyclines Strike Back
EravacyCline is a new tetracycline antibiotic with a broad spectrum of activity that has demonstrated efficacy in the treatment of cIAIs and although it has activity against multidrug-resistant organisms, data are limited for other indications.
Interplay between Rapid Diagnostic Tests and Antimicrobial Stewardship Programs among Patients with Bloodstream and Other Severe Infections.
- Maya Beganovic, E. McCreary, M. Mahoney, B. Dionne, D. Green, T. Timbrook
- Medicine, BiologyThe journal of applied laboratory medicine
- 1 January 2019
The demonstrated clinical value of longer-standing technologies and implications of newer RDTs from an antimicrobial stewardship perspective are explored, particularly those that perform organism identification and genotypic resistance detection, phenotypic susceptibility testing, and direct specimen testing.